Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Discovery of novel therapeutic opportunities for EOC is important for the improvement of clinical outcome of the patients. Emerging evidence is suggesting that epithelial-mesenchymal transition (EMT) plays a crucial role in the aggressiveness in EOC including increasing migration and invasion ability, contributing to chemoresistance and cancer stem cell populations. Targeting EMT in EOC thus offers an attractive therapeutic option.
Department of Obstetrics & Gynaecology, National University Hospital, Singapore. ruby_yj_huang@nuhs.edu.sg
Ruby Yun-Ju
RY
Huang
Vin Yee
VY
Chung
Jean Paul
JP
Thiery
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism*; D000077216:Carcinoma, Ovarian Epithelial; D016503:Drug Delivery Systems / Q000639:trends*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000502:physiology; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D009361:Neoplasm Invasiveness / Q000235:genetics; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology
D000970:Antineoplastic Agents